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For decades, the management of women with recurrent 
or persistent cervical cancer not amenable to surgery 
and women who present with metastatic disease has 
constituted a high unmet clinical need, with platinum-based 
chemotherapy being palliative and associated with short-
lived responses, rapid deterioration in quality of life, and 
early death (median overall survival 7–12 months).1 Some 
progress has been made following the publication of the 
phase 3 randomised Gynecologic Oncology Group (GOG) 
240 trial;1 patients who received the anti-angiogenic drug 
bevacizumab in addition to chemotherapy had a signiﬁ cant 
overall survival advantage over those who did not (median 
17 months vs 13·3 months; HR 0·71 [98% CI 0·54–0·95]; 
p=0·004). In addition to overall survival, both progression-
free survival (median 8·2 months vs 5·9 months) and the 
proportion of patients who achieved an objective tumour 
response  (48% vs 36%) were signiﬁ cantly improved 
with the combination of bevacizumab with either of two 
chemotherapy doublets (cisplatin–paclitaxel or topotecan–
paclitaxel).1 None of these ﬁ ndings were accompanied by a 
signiﬁ cant deterioration in quality of life.2 These results led 
directly to the approval of bevacizumab by the US Food and 
Drug Administration and the European Medicines Agency.
In The Lancet Oncology, Paul Symonds and colleagues3 
report the results of the randomised phase 2, double-
blind, placebo-controlled CIRCCa trial. The authors report 
signiﬁ cantly improved progression-free survival with six 
cycles of carboplatin–paclitaxel plus daily administration 
of cediranib, continued until disease progression or 
the development of intolerable toxicity (hazard ratio 
0·58 [80% CI 0·40–0·85]; p=0·032).3 Cediranib, a 
VEGFR1–3 oral tyrosine kinase inhibitor, joins TNP-470,4 
pazopanib,5 and bevacizumab1,6 as an anti-angiogenic 
drug with demonstrable activity in cervical cancer, with 
the latter two drugs also inhibiting VEGF-dependent 
signalling.7 Although this trial was not powered to 
assess overall survival, the proportion of patients with 
a response (64%) in the cediranib group is the highest 
reported for any regimen in this disease.3
The use of carboplatin in CIRCCa deserves comment. 
Although the Japanese Clinical Oncology Group (JCOG) 
have shown signiﬁ cant non-inferiority of carboplatin 
in JCOG 0505, a phase 3 randomised trial comparing 
cisplatin–paclitaxel with carboplatin–paclitaxel, they 
also reported that in patients who had never received 
platinum treatment, the cisplatin–paclitaxel treatment 
was superior.8 Although the carboplatin–paclitaxel 
doublet is certainly easier to administer than cisplatin–
paclitaxel, caution should be exercised in women who 
have not previously received any platinum-based therapy 
(eg, those treated with radiotherapy alone for locally 
advanced disease and those who present with FIGO 
IVB tumours), and also in elderly patients and those 
previously treated with extended-ﬁ eld radiation for 
whom carboplatin could prove to be intolerable owing to 
vastly diminished bone marrow reserves.
Unlike in GOG 240, febrile neutropenia was an 
important problem in CIRCCa.1,3 In addition, diarrhoea 
induced by cediranib signiﬁ cantly aﬀ ected one quality-
of-life measure (p=0·030).3 Finally, although the authors 
indicate that cross-trial comparisons are rarely valid, 
treatment-induced grade 2 or greater hypertension (34% 
in CIRCCa vs 25% in GOG 240) might indicate that this 
side-eﬀ ect is a greater problem with cediranib than with 
bevacizumab.1,3 By contrast, cediranib was not associated 
with the development of ﬁ stulae—a disorder that 
occurred in 8·6% of patients treated with chemotherapy 
plus bevacizumab in GOG 240.1,3
Although at quite an early stage in its life cycle, 
cediranib has already had an interesting history. An 
absence of perceived beneﬁ t in colorectal cancer, lung 
cancer, and glioblastoma curtailed enthusiasm for 
further development until the results of CIRCCa and 
the ICON6 ovarian cancer study were made available. 
Importantly, ICON6 represents one of eight pivotal 
phase 3 anti-angiogenesis trials in ovarian cancer, all of 
which met their primary endpoint (progression-free 
survival), with ICON6 being the only study to show an 
overall survival advantage.9 Stalled development of 
cediranib had implications for CIRCCa, but fortunately 
development of the drug has since been resurrected to 
focus on gynaecological malignancies.
Similarities in eligibility criteria between CIRCCa and 
GOG 240 (eg, ECOG performance status restricted to 
0–1 and no previous chemotherapy allowed for recurrent 
disease) suggest that a correlation of the progression-
free survival results might be reasonable (ie, 8·1 months 
in CIRCCa is similar to 8·2 months in GOG 240).1,3 Cost-
eﬀ ectiveness remains an issue,10 especially for low-income 
nations where the incidence of cervical cancer is highest. 
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Given a new treatment standard of chemotherapy plus 
bevacizumab, where to position cediranib is not readily 
discernible. Potential future trial designs might use 
strategies to study chemotherapy plus bevacizumab with 
and without cediranib, or randomisation to cediranib 
maintenance therapy in patients who derive clinical 
beneﬁ t from chemotherapy plus bevacizumab (eg, stable 
disease). If active as a monotherapy, a maintenance 
strategy containing cediranib could have major 
toxicology implications given that the median duration 
of cediranib treatment in both groups in CIRCCa was 
19 weeks and overlapped with chemotherapy. Clearly, 
the results of CIRCCa provide additional clinical evidence 
that VEGF-dependent tumour angiogenesis remains a 
valid target in cervical cancer and that the need to explore 
novel anti-angiogenesis combinations and sequencing is 
implicit.
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 Busulfan-based conditioning regimens: not all partners 
are equal
Since its introduction in 1987, the combination of busulfan 
and cyclophosphamide has been the most frequently 
used non-total body irradiation-containing myeloablative 
regimen for acute myeloid leukaemia throughout the 
world.1 With the introduction of ﬂ udarabine-containing 
reduced conditioning regimens, many investigators 
replaced the cyclophosphamide with ﬂ udarabine in an eﬀ ort 
to reduce the toxic eﬀ ects that were thought to be caused 
by cyclophosphamide metabolites.2–4 The busulfan plus 
ﬂ udarabine regimen has become increasingly popular, and 
although multiple retrospective comparisons have reported 
that the combination of busulfan and ﬂ udarabine is less 
toxic and compares favourably with the classic busulfan plus 
cyclophosphamide regimen, only two randomised trials5,6 
have been done, with conﬂ icting results. Both trials were 
hampered by sample size and patient heterogeneity.
In The Lancet Oncology, Alessandro Rambaldi and 
colleagues report the results of a multicentre, randomised 
trial done through the Gruppo Italiano de Trapianto 
Midollo Osseo (GITMO) network, which compared 
busulfan plus cyclophosphamide with busulfan plus 
ﬂ udarabine.7 The trial was restricted to patients with acute 
myeloid leukaemia aged older than 40 years. 252 patients 
were randomly assigned to receive intravenous busulfan 
(12·8 mg/kg), in combination with cyclophosphamide 
(120 mg/kg) or ﬂ udarabine (160 mg/m²). 1-year non-
relapse mortality was 17·2% (95% CI 11·6–25·4) in the 
busulfan plus cyclophosphamide group compared with 
7·9% (4·3–14·3) in the busulfan plus ﬂ udarabine group 
(p=0·026), and this diﬀ erence remained signiﬁ cant 
even at 2 and 5 years after transplantation. However, no 
signiﬁ cant diﬀ erence existed in 5-year leukaemia-free 
survival between the two groups (42·9% [34·4–53·6] for 
busulfan plus cyclophosphamide vs 51·8% [43·6–61·7] 
for busulfan plus ﬂ udarabine; p=0·29). 1-year 
cumulative relapse was similar between groups (22·1% 
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